Human genetic variants in SLC39A8 impact uptake and steady-state metal levels within the cell
Life Science Alliance · 2025-04 · 8 (4) · e202403028
DOI: 10.26508/lsa.202403028 ↗Kurz gefasst
Fachartikel in der Zeitschrift Life Science Alliance, online erschienen am 30.01.2025. Verfasst von Wen-An Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria. Hauptthemen laut MEDLINE: Cation Transport Proteins, Metals, Genetic Variation. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Innovative Medicines Initiative 2, Austrian Academy of Sciences.
Abstract (Originalsprache)
The human SLC39A8 ( hSLC39A8 ) gene encodes a plasma membrane protein SLC39A8 (ZIP8) that mediates the specific uptake of the metals Cd 2+ , Mn 2+ , Zn 2+ , Fe 2+ , Co 2+ , and Se 4+ . Pathogenic variants within hSLC39A8 are associated with congenital disorder of glycosylation type 2 (CDG type II) or Leigh-like syndrome. However, numerous mutations of uncertain significance are also linked to different conditions or benign traits. Our study characterized 21 hSLC39A8 variants and measured their impact on protein localization and intracellular levels of Cd 2+ , Zn 2+ , and Mn 2+ . We identified four variants that disrupt protein expression, five variants with high retention in the endoplasmic reticulum, and 12 variants with localization to the plasma membrane. From the 12 variants with plasma membrane localization, we identified three with complete loss of detectable ion uptake by the cell and five with differential uptake between metal ions. Further in silico analysis on protein stability identified variants that may affect the stability of homodimer interfaces. This study elucidates the variety of effects of hSLC39A8 variants on ZIP8 and on diseases involving disrupted metal ion homeostasis.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
- Centro Interdisciplinario de Neurociencia de Valparaíso, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile.
- Instituto de Neurociencia, Facultad de Ciencias, Universidad de Valparaíso, Valparaíso, Chile.
- Instituto de Sistemas Complejos de Valparaíso (ISCV), Valparaíso, Chile.
- Bayer AG, Pharmaceuticals, Wuppertal, Germany.
- Pfizer Worldwide Research, Development and Medical, Stockholm, Sweden.
ORCID-Profile: Wen-An Wang, Barbara Steurer, Tabea Wiedmer, Giulio Superti-Furga
Förderung
- Innovative Medicines Initiative 2
- Austrian Academy of Sciences
Zitieren
APA
Wang, W. A., Garofoli, A., Ferrada, E., Klimek, C., Steurer, B., Ingles-Prieto, A., Osthushenrich, T., MacNamara, A., Malarstig, A., Wiedmer, T., & Superti-Furga, G. (2025). Human genetic variants in SLC39A8 impact uptake and steady-state metal levels within the cell. Life Science Alliance, 8(4), e202403028. https://doi.org/10.26508/lsa.202403028
Vancouver
Wang WA, Garofoli A, Ferrada E, Klimek C, Steurer B, Ingles-Prieto A, et al. Human genetic variants in SLC39A8 impact uptake and steady-state metal levels within the cell. Life Science Alliance. 2025;8(4):e202403028. doi:10.26508/lsa.202403028
BibTeX
@article{Wang2025,
author = {Wang, Wen-An and Garofoli, Andrea and Ferrada, Evandro and Klimek, Christoph and Steurer, Barbara and Ingles-Prieto, Alvaro and Osthushenrich, Tanja and MacNamara, Aidan and Malarstig, Anders and Wiedmer, Tabea and Superti-Furga, Giulio},
title = {Human genetic variants in SLC39A8 impact uptake and steady-state metal levels within the cell},
journal = {Life Science Alliance},
year = {2025},
volume = {8},
number = {4},
pages = {e202403028},
doi = {10.26508/lsa.202403028}
}
EUVIMED